EnGene Therapeutics starts BLA submission for detalimogene in 4Q 2026
EnGene Therapeutics initiated its BLA submission for detalimogene, planned for 4Q 2026.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.